Dose-dependent association of naldemedine and magnesium o...

연구 요약

Dose-dependent association of naldemedine and magnesium oxide in the management of opioid-induced constipation.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 학술지에 발표된 이 연구는 Hoshino R, Ishihara M, Watanabe D 외 연구팀이 수행하였습니다.

핵심 내용

PURPOSE: This study aimed to evaluate the efficacy and potential pharmacological interaction of naldemedine and magnesium oxide (MgO) in the management of opioid-induced constipation (OIC) in cancer patients, with a particular focus on the impact of different MgO doses on treatment outcomes. METHODS: A total of 171 patients who received opioid therapy were included in this study. The outcome variable was defecation. Daily defecation status during the observation period was extracted from electronic medical records. To assess the effects and potential interaction between naldemedine and MgO on defecation, a generalized estimating equations (GEE) model with a logit link function was used to account for within-patient clustering. Predicted probabilities of defecation were calculated based on the fitted GEE model. RESULTS: The probability of defecation increased with higher doses of MgO. Among patients receiving both MgO and naldemedine, the likelihood of defecation was significantly higher at MgO doses ≤ 1500 mg compared to those receiving MgO alone. However, at doses > 1500 mg, naldemedine did not add further benefit. Naldemedine was independently associated with improved bowel movements, regardless of MgO use. The association between MgO and defecation also strengthened with increasing doses. No significant interaction between naldemedine and MgO was observed at any dose.

일반인을 위한 해석

이 연구는 약물 또는 영양제의 안전한 사용에 관한 과학적 근거를 제공할 수 있습니다. 다만, 개별 연구 결과만으로 일반화하기는 어려우며, 추가적인 연구가 필요할 수 있습니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41779191)